ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.80
-0.31%
US Tech 100
18,212.40
-0.11%
S&P 500
5,308.26
-0.25%
US Dollar vs CAD
1.36697
0.21%
Bitcoin
69,863.24
-0.38%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. FibroGen Inc (FGEN)

  7. FibroGen Inc (FGEN) News

FGEN

FibroGen (FGEN)

FibroGen Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:FGEN
DateTimeSourceHeadlineSymbolCompany
05/07/202410:55AMAllPennyStocks.comTraders Rush To Buy Biotech Following Q1 Earnings BeatNASDAQ:FGENFibroGen Inc
05/07/20246:00AMGlobeNewswire Inc.FibroGen to Participate in Upcoming Investor ConferencesNASDAQ:FGENFibroGen Inc
05/06/20243:10PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FGENFibroGen Inc
05/06/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:FGENFibroGen Inc
05/06/20243:02PMGlobeNewswire Inc.FibroGen Reports First Quarter 2024 Financial ResultsNASDAQ:FGENFibroGen Inc
04/29/20246:00AMGlobeNewswire Inc.FibroGen to Report First Quarter 2024 Financial ResultsNASDAQ:FGENFibroGen Inc
04/24/20243:02PMGlobeNewswire Inc.FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology ANASDAQ:FGENFibroGen Inc
04/02/20244:46PMGlobeNewswire Inc.FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate CancerNASDAQ:FGENFibroGen Inc
03/26/20246:00AMGlobeNewswire Inc.FibroGen to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:FGENFibroGen Inc
03/11/20246:00AMGlobeNewswire Inc.FibroGen Appoints Deyaa Adib, M.D. as Chief Medical OfficerNASDAQ:FGENFibroGen Inc
03/08/20246:19PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
03/08/20246:18PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
03/08/20246:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
02/26/20243:08PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:FGENFibroGen Inc
02/26/20243:06PMGlobeNewswire Inc.FibroGen Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
02/26/20243:05PMGlobeNewswire Inc.FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South KoreaNASDAQ:FGENFibroGen Inc
02/23/20247:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
02/23/20247:29PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
02/23/20247:28PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
02/20/20246:00AMGlobeNewswire Inc.FibroGen to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
02/14/20242:37PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:FGENFibroGen Inc
02/05/20247:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
02/05/20246:00AMGlobeNewswire Inc.FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024NASDAQ:FGENFibroGen Inc
01/25/20246:00AMGlobeNewswire Inc.FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic CancerNASDAQ:FGENFibroGen Inc
12/26/20236:28PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
12/11/20233:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
12/11/20233:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
12/11/20233:19PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
12/09/20234:02PMGlobeNewswire Inc.FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual MeetingNASDAQ:FGENFibroGen Inc
11/06/20233:11PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FGENFibroGen Inc
 Showing the most relevant articles for your search:NASDAQ:FGEN

Your Recent History

NASDAQ
MKUL
Molekule
LSE
HGTS
BOV
VALEF502
VALEF502 Ex:47,49
NYSE
PPF
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved